antibodies

IMPACT FACTOR 3.0 | Indexed in: PubMed | CITESCORE 7.1

an Open Access Journal by MDPI

Nanobody

Guest Editors:

Prof. Dr. Ulrich Rothbauer
Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany

Dr. Patrick Chames
Aix-Marseille Université, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, F-13009 Marseille, France

Deadline for manuscript submissions:
closed (30 November 2018)

Message from the Guest Editors

Dear Colleagues,

Since their first description 25 years ago, single-domain antibody fragments, derived from heavy-chain-only antibodies of camelids, so-called nanobodies, have emerged as attractive alternatives to conventional antibodies for multiple applications in biomedical research. Compared to other small antibody fragments like Fab or scFv, nanobodies have numerous advantages.

To date nanobodies have become outstanding tools for in vitro and in vivo imaging, as well as structural and proteome analysis. As genetically encoded intrabodies, they open new possibilities for visualization or functional studies on proteins in living cells. The recently described advances in identification of antigen-specific nanobodies from synthetic gene libraries now makes nanobody-based approaches broadly available to many researches in the field.

This Special Issue is aimed to provide an up-to-date overview of the rising field of nanobodies including generation and functionalization of nanobodies as well as their application for immunoassays, proteomics, protein crystallization and in vitro and in vivo imaging.

Prof. Ulrich Rothbauer
Dr. Patrick Chames
Guest Editor

antibodies

IMPACT FACTOR 3.0 | Indexed in: PubMed | CITESCORE 7.1

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra
Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: CiteScore - Q2 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
𝕏@Antibodies_MDPI